Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 12;10(4):731.
doi: 10.3390/jcm10040731.

Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease

Affiliations

Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease

Matthias Kelm et al. J Clin Med. .

Abstract

Despite the increasing incidence and prevalence of Crohn's Disease (CD), no curative options exist and treatment remains complex. While therapy has mainly focused on medical approaches in the past, growing evidence reveals that in cases of limited inflammation, surgery can suffice as an alternative primary treatment. We retrospectively assessed the disease course and outcomes of 103 patients with terminal Ileitis who underwent primary surgery (n = 29) or received primary medical treatment followed by surgery (n = 74). Primary endpoint was the need for immunosuppressive medication after surgical treatment (ileocecal resection, ICR) during a two-years follow-up. Rates for laparoscopic ICR were enhanced in case of early surgery, but no differences were seen for postoperative complications. In case of immunosuppressive medication, patients with ICR at an early state of disease needed significantly less anti-inflammatory medication during the two-year postoperative follow-up compared to patients who were primarily treated medically. Furthermore, in a subgroup analysis for patients with localized ileocecal disease manifestation, early surgery consistently resulted in a decreased amount of medical therapy postoperatively. In conclusion primary ICR is safe and effective in patients with limited CD, and the need for immunosuppressive medication during the postoperative follow-up is low compared to patients receiving surgery at a later stage of disease.

Keywords: Crohn’s Disease; ileocecal resection; surgical therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Study design.

References

    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C., Chan F.K., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Kappelman M.D., Rifas-Shiman S.L., Porter C.Q., Ollendorf D.A., Sandler R.S., Galanko J.A., Finkelstein J.A. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. doi: 10.1053/j.gastro.2008.09.012. - DOI - PMC - PubMed
    1. Hisamatsu T., Matsumoto T., Watanabe K., Nakase H., Motoya S., Yoshimura N., Ishida T., Kato S., Nakagawa T., Esaki M., et al. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn’s Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study] J. Crohns Colitis. 2019;13:1097–1104. doi: 10.1093/ecco-jcc/jjz030. - DOI - PubMed
    1. Voskuil M.D., Bangma A., Weersma R.K., Festen E.A.M. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J. Gastroenterol. 2019;25:2539–2548. doi: 10.3748/wjg.v25.i21.2539. - DOI - PMC - PubMed
    1. Pillai N., Dusheiko M., Maillard M.H., Rogler G., Brüngger B., Bähler C., Pittet V.E.H. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. J. Crohns Colitis. 2019;13:744–754. doi: 10.1093/ecco-jcc/jjz003. - DOI - PubMed

LinkOut - more resources